Z01 BC 010704 (Z01) | |||
---|---|---|---|
Title | Inhibition of Grb2 mediated cellular signaling | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Roller, Peter | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $19,520 | Project Dates | 10/01/2006 - 04/30/2007 |
Fiscal Year | 2007 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Chemoprevention (20.0%) Neurosciences Research (25.0%) |
Brain (25.0%) Breast (55.0%) Nervous System (25.0%) |
||
Research Type | |||
Cancer Progression and Metastasis Chemoprevention |
|||
Abstract | |||
We developed lead structures that are unique in that they are not dependent on the phosphotyrosine motif for inhibitory action. One agent, termed RRK-169, was effective in inhibiting Grb2-SH2 domain association with the erbB2 receptor in intact MDA-453 breast cancer cells, at low micromolar concentration. We developed a concise route for the efficient synthesis of G1TE analogs on solid phase. Using this route, a series of cyclic peptides that do not rely on phosphotyrosine or its mimics were designed and synthesized based upon the phage library derived cyclopeptide, G1TE. Considering that Gly7 plays prominent roles for G1TE binding to the Grb2-SH2 domain, we introduced different amino acids in the 7th position. The D-Ala7-containing peptide RRK-178 demonstrates improved binding affinity by adopting favorable conformation for protein binding. This can be rationalized by molecular modeling. The optimization at the Leu2 position was also studied, and the resulting cyclopeptides exhibited remarkably improved binding affinity. Based upon these global modifications, a highly potent peptide ligand RRK-199 was discovered with a Kd= 17 nM, evaluated by Biacore binding assay. This new analog is one of the most potent non-phosphorus-containing Grb2-SH2 antagonists reported to date. This potent peptidomimetic provides a new template for the development of non-pTyr containing Grb2-SH2 domain antagonists and acts as a chemotherapeutic lead for the treatment of erbB2-related cancer. |